Novanta (NOVT) Resumen de Acciones
Novanta Inc., junto con sus filiales, ofrece medicina de precisión, fabricación de precisión, soluciones médicas, soluciones de robótica y automatización y soluciones de cirugía avanzada en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 1/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
NOVT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Novanta Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$146.62 |
| Máximo en las últimas 52 semanas | US$171.85 |
| Mínimo de 52 semanas | US$98.27 |
| Beta | 1.68 |
| Cambio en 1 mes | -8.67% |
| Variación en 3 meses | 15.95% |
| Cambio de 1 año | 17.56% |
| Variación en 3 años | -18.31% |
| Variación en 5 años | 9.79% |
| Variación desde la OPV | 819.96% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 17
NOVT: Future Earnings Power Will Rely On Executing Riverpoint Acquisition Strategy
Analysts have adjusted their fair value estimate for Novanta to $175.0 from $171.5, citing updated models that incorporate recent Q1 results, accelerating bookings and growth momentum, along with a revised future P/E assumption of 34.67x. Analyst Commentary Recent Street commentary on Novanta focuses on how the latest Q1 results and updated models feed into valuation, execution risk and future growth assumptions for the stock.Seeking Alpha • Jun 11
Novanta: An Interesting Deal Accelerates Growth
Summary Novanta announced a substantial $1.45B acquisition of Riverpoint Medical, doubling recurring medical consumables revenue and increasing medical end-market concentration to 60%. Riverpoint brings high-margin, fast-growing consumables, with 12-15% organic growth and 40% EBITDA margins, enhancing Novanta's profitability profile. Pro forma leverage rises to 2.7x; a $300M equity raise at a discount offsets some debt but results in 3% dilution. Despite strong execution and growth momentum, Novanta trades at ~40x forward earnings, leading me to remain cautious and await better entry points. Read the full article on Seeking AlphaActualización de narrativa • Jun 02
NOVT: Future Earnings Power Will Rely On Sustaining Bookings Strength And Margin Execution
Analysts have lifted their fair value estimate for Novanta stock from $157 to about $171.50, citing updated models that reflect Q1 results with accelerating bookings and ongoing growth momentum. Analyst Commentary Bullish Takeaways Bullish analysts point to accelerating Q1 bookings as a key support for a higher fair value range, seeing healthier near term demand feeding into updated models.Recent updates
Actualización de narrativa • Jun 17
NOVT: Future Earnings Power Will Rely On Executing Riverpoint Acquisition Strategy
Analysts have adjusted their fair value estimate for Novanta to $175.0 from $171.5, citing updated models that incorporate recent Q1 results, accelerating bookings and growth momentum, along with a revised future P/E assumption of 34.67x. Analyst Commentary Recent Street commentary on Novanta focuses on how the latest Q1 results and updated models feed into valuation, execution risk and future growth assumptions for the stock.Seeking Alpha • Jun 11
Novanta: An Interesting Deal Accelerates Growth
Summary Novanta announced a substantial $1.45B acquisition of Riverpoint Medical, doubling recurring medical consumables revenue and increasing medical end-market concentration to 60%. Riverpoint brings high-margin, fast-growing consumables, with 12-15% organic growth and 40% EBITDA margins, enhancing Novanta's profitability profile. Pro forma leverage rises to 2.7x; a $300M equity raise at a discount offsets some debt but results in 3% dilution. Despite strong execution and growth momentum, Novanta trades at ~40x forward earnings, leading me to remain cautious and await better entry points. Read the full article on Seeking AlphaActualización de narrativa • Jun 02
NOVT: Future Earnings Power Will Rely On Sustaining Bookings Strength And Margin Execution
Analysts have lifted their fair value estimate for Novanta stock from $157 to about $171.50, citing updated models that reflect Q1 results with accelerating bookings and ongoing growth momentum. Analyst Commentary Bullish Takeaways Bullish analysts point to accelerating Q1 bookings as a key support for a higher fair value range, seeing healthier near term demand feeding into updated models.Artículo de análisis • May 15
Novanta Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a pretty great week for Novanta Inc. ( NASDAQ:NOVT ) shareholders, with its shares surging 14% to US$156 in...Actualización de narrativa • Apr 19
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.Actualización de narrativa • Apr 05
NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.Actualización de narrativa • Mar 22
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.Actualización de narrativa • Mar 06
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.Actualización de narrativa • Feb 20
NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.Actualización de narrativa • Feb 06
NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).Actualización de narrativa • Jan 22
NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.Actualización de narrativa • Jan 08
NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.Actualización de narrativa • Dec 24
NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.Actualización de narrativa • Dec 10
NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).Actualización de narrativa • Nov 26
NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.Actualización de narrativa • Nov 10
NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.Artículo de análisis • Oct 28
Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Novanta Inc. ( NASDAQ:NOVT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...Artículo de análisis • Oct 07
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Novanta Inc. ( NASDAQ:NOVT ), is not the largest company out there, but it received a lot of attention from a...Artículo de análisis • Sep 13
Novanta's (NASDAQ:NOVT) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Actualización de narrativa • Sep 05
Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.Artículo de análisis • Aug 29
Novanta Inc.'s (NASDAQ:NOVT) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 69.2x Novanta Inc. ( NASDAQ:NOVT ) may be sending very bearish signals at...Seeking Alpha • Apr 06
Novanta: A Trusted Yet Premium Technology Partner
Summary Novanta has shown solid growth over the past decade, but growth has been a bit sluggish in recent years. The company is a key technology partner for global OEMs, with balanced revenue from advanced industrial and medical applications, boasting strong EBITDA margins. Despite a recent acquisition and increased sales, competitive dynamics, and macroeconomic challenges have pressured growth; shares are now trading at a lower, yet still premium, multiple. With debt reduced and growth returning, shares deserve a premium, but need to fall below $100 for a more attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Jan 01
Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Summary Novanta's Q3 results show revenue growth but a decline in gross margin and shipment deferrals, indicating prolonged challenges. Macroeconomic pressures, including weak demand and high interest rates, are hindering recovery in the life sciences sector. The company's book-to-bill ratio below 1 signals weakening demand, and its high debt levels add to the risk. Novanta’s valuation is too high given its low growth prospects, especially compared to more promising peers. As a result of these factors, Novanta is downgraded from a hold to a sell, as its current price does not justify the risks. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Summary Novanta Inc. is a leading tech provider facing macroeconomic headwinds and a soft demand climate, which have pressured its revenue and profitability. Despite strong fundamentals and a solid market position, its current high valuation makes it a risky investment. NOVT has managed modest revenue growth but struggles with significant inflationary challenges. For now, a Hold rating is recommended as the stock's valuation does not align with its performance amidst ongoing market uncertainties. Read the full article on Seeking Alpha
Nueva narrativa • Aug 28
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.Rentabilidad de los accionistas
| NOVT | US Electronic | Mercado US | |
|---|---|---|---|
| 7D | -0.8% | -4.6% | -0.9% |
| 1Y | 17.6% | 69.9% | 19.4% |
Rentabilidad vs. Industria: Los resultados de NOVT fueron inferiores a los de la industria US Electronic, que obtuvo un rendimiento del 69.9% el año pasado.
Rentabilidad vs. Mercado: NOVT obtuvo unos resultados inferiores a los del mercado US, que fueron del 19.4% el año pasado.
Volatilidad de los precios
| NOVT volatility | |
|---|---|
| NOVT Average Weekly Movement | 7.9% |
| Electronic Industry Average Movement | 9.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: NOVT no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NOVT (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1968 | 3,000 | Matthijs Glastra | www.novanta.com |
Novanta Inc., junto con sus filiales, ofrece medicina de precisión, fabricación de precisión, soluciones médicas, soluciones de robótica y automatización y soluciones de cirugía avanzada en Estados Unidos y a escala internacional. La empresa opera en los segmentos de tecnologías de automatización y soluciones médicas. El segmento de medicina y fabricación de precisión diseña, fabrica y comercializa soluciones de dirección y escaneado de haces láser, fuentes láser, movimiento robótico y de precisión, herramientas robóticas de fin de brazo y husillos de cojinetes.
Resumen de fundamentos de Novanta Inc.
| Estadísticas fundamentales de NOVT | |
|---|---|
| Capitalización bursátil | US$5.66b |
| Beneficios(TTM) | US$53.72m |
| Ingresos (TTM) | US$1.00b |
103.0x
Ratio precio-beneficio (PE)5.5x
Ratio precio-ventas (PS)¿Está NOVT sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NOVT | |
|---|---|
| Ingresos | US$1.00b |
| Coste de los ingresos | US$560.43m |
| Beneficio bruto | US$444.51m |
| Otros gastos | US$390.79m |
| Beneficios | US$53.72m |
Últimos beneficios comunicados
Apr 03, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 1.42 |
| Margen bruto | 44.23% |
| Margen de beneficio neto | 5.35% |
| Ratio deuda/patrimonio | 18.4% |
¿Cómo se ha desempeñado NOVT a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/14 01:15 |
| Precio de las acciones al final del día | 2026/07/14 00:00 |
| Beneficios | 2026/04/03 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Novanta Inc. está cubierta por 8 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |